Natural Cellular Zeolite & Autism Study
Enclosed is an announcement that the FDA sanctioned scientific
study using NCD with autistic children has been approved.
May many benefit from the information obtained.
Natural Cellular Defense (NCD), a safe, natural, inert mineral
supplement has generated many encouraging reports from parents
of autistic children. NCD has attracted the interest of some
of the leading autism researchers and physicians. A randomized,
double-blind, placebo-controlled study designed to evaluate
the benefits of NCD Zeolite on Autism Spectrum Disorders was
approved by BioMed IRB on June 7, 2006.
San Diego, California - June 7, 2006
BioMed IRB of San Diego, California has approved a clinical
trial that seeks to evaluate the benefits of adding a patented
supplement, NCD zeolite, to the diet of children diagnosed
with Autism Spectrum Disorders. Natural Cellular Defense is
purified clinoptilolite, a type of zeolite, suspended in solution.
The zeolite is purified using a patented process and named
NCD Zeolite£.
This form of zeolite is one of the few negatively charged
minerals in nature, and it has a microscopic honeycomb-like
crystalline structure of cavities and cages. Animal studies
show that they have the ability to attract, trap, bind and
remove various heavy metals and toxins such as mercury, lead
and arsenic.
The study's eighty autistic children will be divided into
two groups. One group is receiving the NCD zeolite and the
other the placebo for ninety days. Both groups will be measured
using a variety of established instruments for autism diagnosis
and treatment evaluation. Further, since other animal and
human studies with zeolite have demonstrated the ability for
zeolite to remove heavy metals, a portion of the participants
will receive a series of urine excretion tests designed to
detect levels of heavy metal excretion. If previous studies
in adults hold true for these autistic children, the researchers
may see excretion rates as high as 10 times over their baseline.
At the end of the ninety day study period, those receiving
the placebo will then begin taking the NCD and be tracked
for ninety more days.
Two sites have been approved so far. In Plano, Texas, Dr.
Seshagiri Rao, a Board Certified Pediatrician is the lead
investigator. The second site, in Baton Rouge, Louisiana is
lead by Dr. Stephanie Cave. Both sites have begun recruiting
for study participants. Visit www.ZeoliteAutismStudy.com to
learn how to apply.
Professor James Adams, PhD will conduct the study data analysis.
Dr. Adams has reviously published studies on the high level
of mercury toxicity common in many autistic children. Other
studies suggest a possible link between Thirmersol concentration
found in many vaccines and the high mercury levels in autistic
children.
--------------------
To apply for the study send the following information to
the study coordinator.* Contact information: Name, address,
phone
* Child's name and birthdate
* Brief description of child's asd and treatment history
After receipt, you'll receive an email with additional information
and a copy of the Autism Treatment Evaluation Checklist (ATEC)
and the Pervasive Developmental Disorder Behavioural Inventory
(PDD-BI).
Thanks to Jason D. Groode
|
